The mammalian target of rapamycin (mTOR) is also reported to control glycolytic metabolism in GBM through the forkhead box class O1 (FoxO1) transcription factor and c-Myc upregulation in an Akt-independent manner17. This evidence concerns the gene AKT1 and glioblastoma.